Biotech

Nikon CeLL unveils Cell Therapy in Japan with RoosterBio

Nikon CeLL Innovation Co., Ltd. (NCLi), a subsidiary of Nikon Corporation, has entered into a strategic licensing agreement with RoosterBio, Inc., a U.S.-based leader in stem cell technology. This partnership aims to establish a comprehensive platform for the development and GCTP/GMP-compliant manufacturing of human mesenchymal stem cells (MSCs) and extracellular vesicle (EV) therapeutics in Japan. Through this agreement, Japan’s biopharmaceutical sector gains access to an end-to-end solution for MSC and EV therapy development. Drug developers can utilize RoosterBio’s advanced technology platform to accelerate early-stage development with NCLi and seamlessly transition into clinical manufacturing within NCLi’s purpose-built GCTP/GMP facility for cell therapies. Also Read: Astellas and YASKAWA Form Joint Venture to Advance Automated Cell Therapy Manufacturing The collaboration enables NCLi to support a full range of capabilities-including cell expansion, harvesting, formulation,…